Oral Science pursues its engagement to provide effective and innovative solutions to Canadian dental professionals by launching Fluorimax™, the next generation of fluoride varnishes: colophony-free and offering better fluoride uptake than colophony-based varnishes, a non-tacky coating, an enhanced patient experience and a lower cost. Developed and manufactured by Elevate Oral Care (Florida, USA) and containing 2.5% sodium fluoride, Fluorimax™ (NPN 80072804), will be distributed in Canada exclusively by Oral Science.
Widely used in the dental industry as a gold standard treatment for caries prevention, dental varnishes all have 5% of sodium fluoride as their medicinal ingredient. Typically, they also contain colophony, a natural resin obtained from pine or cone trees that can create allergic reactions amongst certain patients. Fluorimax™ patented technology is based on studies demonstrating that enamel has a saturation point and only a specific quantity of fluoride can be absorbed by the tooth. Instead of colophony, it contains dewaxed, food grade shellac, a thinner resin that dries seven times thinner than the standard colophony, forcing more sodium fluoride to the surface of the varnish when applied to the tooth.
“Fluorimax™ is dispensed from a 12ml bottle. There is no need for a uni-dose, so only the needed quantity is applied, which keeps the cost per application very low. For the patients, it is ideal since they will not get a tacky or stinging sensation because the formula dries to a thin coating. Additionally, no post-treatment instructions are required. Finally, there is no need to worry anymore about potential allergic reactions due to the colophony. Fluorimax™ is definitely the thinnest, most efficient, safest and comfortable varnish dental hygienists can provide their patients.” said Steve Pardue, co-founder and product specialist at Elevate Oral Care.
“We are proud to offer a truly new generation of dental varnishes that significantly increases both the patients’ and dental hygienists experience. We strongly believe the efficacy of there high risk caries treatment will be enhanced.” commented Daniel Ménard, CEO and co-founder of Oral Science.